Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Aug 11;128(6):745-6.
doi: 10.1182/blood-2016-06-722462.

DMF: a promising therapeutic option in CTCL

Ivana Vancurova  1
Affiliations
Comment

DMF: a promising therapeutic option in CTCL

Ivana Vancurova. Blood. .

Abstract

In this issue of Blood, Nicolay et al present their exciting findings that show that dimethyl fumarate (DMF) specifically inhibits NF-κB activity in cutaneous T-cell lymphoma (CTCL) cells, thus inducing their apoptosis, while having minimal effect on healthy T cells (see figure). Their study suggests that DMF may represent a new promising therapeutic option in CTCL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
Mechanism of DMF action in CTCL. DMF specifically inhibits NF-κB activity in CTCL cells, thus inducing their apoptosis, while having minimal effect on healthy T cells. Professional illustration by Patrick Lane, ScEYEnce Studios.
See this image and copyright information in PMC

Comment on

References

    1. Nicolay JP, Müller-Decker K, Schroeder A, et al. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB. Blood. 2016. 128(6):805-815. - PMC - PubMed
    1. Olsen E, Vonderheid E, Pimpinelli N, et al. ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722. - PubMed
    1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1–223.e17. - PubMed
    1. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood. 2016;127(25):3142–3153. - PubMed
    1. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood. 2006;107(6):2354–2363. - PubMed